Pelthos Therapeutics sells FDA approved prescription skin treatments for molluscum contagiosum and impetigo from its base in Durham, North Carolina. PTHS reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | Lake Street | Maintained | Buy | |
| Aug 14 | Oppenheimer | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in PTHS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTHS is in one of them and how their past PTHS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PTHS in an article yet. Here's the latest on the wider market.
About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company based in Durham, North Carolina. It sells prescription skin treatments that have been approved by the U.S. Food and Drug Administration. Its main products are ZELSUVMI, a topical gel for molluscum contagiosum, a common viral skin infection, and XEPI, a cream for impetigo, a bacterial skin infection. The products are used by patients, parents and caregivers, and are prescribed by dermatologists and pediatricians.
- Headquarters
- Durham, NC